|
Aug 29
|
Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
|
|
Aug 27
|
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
|
|
Aug 27
|
High Growth Tech Stocks To Watch: Vertex And 2 Other Top Picks
|
|
Jun 13
|
Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
|
|
Jun 11
|
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
|
|
May 17
|
Insider Sale: Chief Legal Officer of Zai Lab Ltd (ZLAB) Sells Shares
|
|
May 16
|
Zai Lab Announces Participation in May and June Investor Conferences
|
|
May 14
|
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
|
|
May 13
|
BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC
|
|
May 13
|
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
|
|
May 11
|
Zai Lab Limited (NASDAQ:ZLAB) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
|
|
May 10
|
Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
|
|
Apr 30
|
Zai Lab Limited's (NASDAQ:ZLAB) Profit Outlook
|
|
Apr 15
|
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
|
|
Apr 11
|
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
|
|
Apr 2
|
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
|
|
Apr 1
|
Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago
|
|
Apr 1
|
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
|
|
Mar 27
|
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
|